Extension Program for Bay 43-9006

Completed · Phase 2

Conditions studied: Neoplasm, Metastasis

In brief

The study was designed to allow for the continuation of treatment with Sorafenib as a single agent to those patients who participated in a previous Sorafenib study that had reached its designated end-date and who were, in the opinion of the Investigator and the Sponsor, still benefiting from treatment.

Key facts

Study ID

NCT00657254

Run by

Bayer

People needed

9

Starts

2002-12-01

Expected to finish

2005-06-01

Last updated by the study team

2014-12-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Study site — Boston, Massachusetts, United States
• Study site — Bruxelles - Brussel, Belgium
• Study site — Hamilton, Ontario, Canada
• Study site — Toronto, Ontario, Canada
• Study site — Essen, North Rhine-Westphalia, Germany
• Study site — Herne, North Rhine-Westphalia, Germany

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.